In vitro biocompatibility assessment of functionalized magnetite nanoparticles: Biological and cytotoxicological effects
Source abstract
Abstract
Abstract In the biomedical field, nanomaterials have the potential for use in the targeted delivery of drugs in the human body and in the diagnosis and therapy of certain diseases. In the category of targeted delivery, magnetite (Fe3O4) nanoparticles have received much attention. As with any similar new therapy, when such nanoparticles are functionalized with chemical groups designed to permit the specific attachment of drugs, cytotoxicological testing is necessary before moving to animal models. Here, we consider several variously functionalized magnetite nanoparticles, including those prepared with (1) a monolayer of oleic acid (Fe3O4@OA), which is subsequently converted to (2) a shell of amine‐containing silane (Fe3O4@NH2), (3) a shell of silica (Fe3O4@SiO2), and (4) a shell of amine‐containing silane over a shell of silica (Fe3O4@SiO2@NH2). These latter three functionalities were evaluated for biocompatibility, cellular morphology, mitochondrial function (MTT assay), lactate dehydrogenase membrane leakage (LDH assay), and proinflammatory potential through enzyme linked immunosorbent assay (ELISA) for interleukin 6 (IL‐6). Controlled tests were performed over a period of 72 h, with results showing LDH leakage and abnormal Il‐6 secretion at high concentrations (>50 μg/mL). The tests showed that, in addition to the surface characteristics of the nanoparticles, both the nutrient medium and the time of suspension before exposure to cells also contribute to nanoparticle cytotoxicity. © 2012 Wiley Periodicals, Inc. J Biomed Mater Res Part A, 2012.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoparticles: synthesis and applications · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (34)
Show source-provided references
1. 10.1016/j.nano.2006.11.00810.1016/j.nano.2006.11.008 ↗
2. 10.1016/j.parkreldis.2007.11.01210.1016/j.parkreldis.2007.11.012 ↗
3. 10.1038/nrn182710.1038/nrn1827 ↗
4. 10.1016/j.jclepro.2007.04.01210.1016/j.jclepro.2007.04.012 ↗
5. Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION)10.3402/nano.v1i0.5358 ↗
6. 10.1002/adma.20080236610.1002/adma.200802366 ↗
7. 10.1038/nature0704810.1038/nature07048 ↗
8. 10.1016/j.taap.2009.07.01910.1016/j.taap.2009.07.019 ↗
9. 10.1016/j.pneurobio.2008.09.00910.1016/j.pneurobio.2008.09.009 ↗
10. 10.1021/nn101557e10.1021/nn101557e ↗
11. 10.1073/pnas.060858210410.1073/pnas.0608582104 ↗
12. 10.1080/0022293070131493210.1080/00222930701314932 ↗
13. 10.1897/08-090.110.1897/08-090.1 ↗
14. pH‐triggered doxorubicin delivery based on hollow nanoporous silica nanoparticles with free‐standing superparamagnetic Fe3O4 cores
15. 10.1021/cm049552x10.1021/cm049552x ↗
16. MoretS. “Synthèse et modification chimique de la surface des nanoparticules de maghémite à des fins d'applications biomédicales “ PH.D. dissertation ‐France . Bordeaux: Université de Bordeaux I;2002.221p.
17. 10.1039/c0jm00283f10.1039/c0jm00283f ↗
18. 10.1186/1743-8977-2-810.1186/1743-8977-2-8 ↗
19. 10.3109/0894193960902585710.3109/08941939609025857 ↗
20. 10.1021/am900028e10.1021/am900028e ↗
21. 10.1016/j.biomaterials.2008.05.01510.1016/j.biomaterials.2008.05.015 ↗
22. 10.1021/nn100561e10.1021/nn100561e ↗
23. 10.1016/j.ejpb.2008.08.00910.1016/j.ejpb.2008.08.009 ↗
24. 10.2214/AJR.09.310710.2214/AJR.09.3107 ↗
25. 10.1002/nbm.92510.1002/nbm.925 ↗
26. 10.1021/nn800596w10.1021/nn800596w ↗
27. The amino‐terminal matrix assembly domain of fibronectin stabilizes cell shape and prevents cell cycle progression10.1242/jcs.112.19.3225 ↗
28. 10.1016/j.biomaterials.2005.02.03610.1016/j.biomaterials.2005.02.036 ↗
29. 10.1016/j.biomaterials.2004.05.02210.1016/j.biomaterials.2004.05.022 ↗
30. 10.1016/j.biomaterials.2003.09.09510.1016/j.biomaterials.2003.09.095 ↗
31. 10.1016/S1748-0132(08)70014-810.1016/S1748-0132(08)70014-8 ↗
32. ATCC. F‐12K Medium Formulation. In: Collection ATC editor.http://www.atcc.org/Attachments/4892.pdf. Manassas USA;2004.
33. 10.1186/1743-8977-4-610.1186/1743-8977-4-6 ↗
34. AllouniZE CimpanMR HolPJ SkodvinT GjerdetNR.Agglomeration and sedimentation of TiO2nanoparticles in cell culture medium Colloids Surf B Biointerfaces2009;68:83–87.10.1016/j.colsurfb.2008.09.014 ↗